Pharma Solutions

Digital evolution of clinical trials

De-risk clinical trials with a turn-key digital biomarker strategy

Accelerate timelines

- Efficient screening
- Interim monitoring
- Early efficacy
- Statistical power with smaller groups

Operationalize state-of-the-art technology

- Democratize trial participation
- Standardized acquisition and analysis
- Enable real-time data accessibility
- Advanced analytics deliver endpoints

Our experience

- Designed and executed 60+ commercial clinical trials
- 600+ sites globally
- 80,000+ participant scans analyzed

Our unique combination of in-house technical knowledge and operational excellence enables biomarker development alongside standardized implementation of digital strategies in global clinical trials.

Perspectum

Quantitative imaging metrics to characterize liver disease



Fat with LiverMultiScan

We implement the gold-standard IDEAL-PDFF (proton density fat fraction) method to provide the most precise measurement of liver fat enabling smaller and more powerful clinical trials



Liver disease activity with LiverMultiScan

Corrected T1 (cT1), our proprietary biomarker, can improve identification of subjects and demonstrate efficacy in as little as six weeks. cT1 has been included as an endpoint in 40+ commercial clinical trials.[1-3]



Multi-organ and multi-modality imaging

Whether you need to monitor bone density as a safety marker, body composition for a combination trial, or the pancreas for off-target effects, we offer a range of imaging services to support your trial needs with a streamlined and standardized service.



Radiology over-reads

Radiology over-reads for incidental findings, cardiac assessment, and tumor response criteria are performed by board-certified radiologists and are delivered alongside other imaging metrics via seamless integration in one dataset.

Streamlined pathology workflow



Streamlined workflow removes unnecessary shipping steps and enables multiple pathologists to report cases in parallel through Paige's best-in-class digital viewing platform. Combined with three-day sample processing and fully automated report generation, our solution allows reports to be delivered to clinical sites in as little as 10 business days from receipt of tissue.

References

1. Harrison, S. A., et al. (2020). J Hepatol, 71(4), 1198–1212.
2. Loomba, R., et al. (2020). J Hepatol, 73, S19–S57.
3. Harrison, S. A., et al. (2021). Hepatol Commun, 5(4), 573-588.

Pharma Solutions

Perspectum

info@perspectum.com | www.perspectum.com | U.S.: (+1) 833 875 0862